TY - JOUR T1 - Quantifying structural connectivity in brain tumor patients JF - medRxiv DO - 10.1101/2021.03.19.21253837 SP - 2021.03.19.21253837 AU - Yiran Wei AU - Chao Li AU - Stephen John Price Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/03/24/2021.03.19.21253837.abstract N2 - Brain tumors are characterised by infiltration along the white matter tracts, posing significant challenges to precise treatment. Mounting evidence shows that an infiltrating tumor can interfere with the brain network diffusely. Therefore, quantifying structural connectivity has potential to identify tumor invasion and stratify patients more accurately. The tract-based statistics (TBSS) is widely used to measure the white matter integrity. This voxel-wise method, however, cannot directly quantify the connectivity of brain regions. Tractography is a fiber tracking approach, which has been widely used to quantify brain connectivity. However, the performance of tractography on the brain with tumors is complicated by the tumor mass effect. A robust method of quantifying the structural connectivity strength in brain tumor patients is still lacking.Here we propose a method which could provide robust estimation of tract strength for brain tumor patients. Specifically, we firstly construct an unbiased tract template in healthy subjects using tractography. The voxel projection of TBSS is employed to quantify the tract connectivity in patients, using the location of each tract fiber from the template. To further improve the standard TBSS, we propose an approach of iterative projection of tract voxels guided by the tract orientation measured using the voxel-wise eigenvectors. Compared to state-of-the-art tractography, our approach is more sensitive in reflecting more functional relevance. Further, the different extent of network disruption revealed by our approach correspond to the clinical prior knowledge of tumor histology. The proposed method could provide a robust estimation of the structural connectivity for brain tumor patients.Competing Interest StatementThe authors have declared no competing interest.Funding StatementSJP acknowledges National Institute for Health Research (NIHR) Career Development Fellowship (CDF-18-11-ST2-003). CL acknowledges Cancer Research UK biomarker grant (CRUK/A19732).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical Committee: The Cambridgeshire 2 LREC, Ethics number: 10/H308/23All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request ER -